ROIV - Roivant Sciences Ltd.
About Roivant Sciences Ltd. (https://roivant.com)
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Mayukh Sukhatme | President, Chief Investment Officer & Director | 1976 | $81,640,782 USD |
| Eric Venker | President & Chief Executive Officer of Immunovant | 1987 | $6,671,119 USD |
| Matthew Gline | Chief Executive Officer & Director | 1984 | $5,715,893 USD |
| Richard Pulik | Chief Financial Officer | 1980 | $1,553,179 USD |
| Jennifer Humes | Chief Accounting Officer | 1982 | $324,640 USD |
| Alex Gasner | Executive Vice President of Roivant Health | – | – |
| Frank Torti | President & Vant Chair | 1979 | – |
| Huafeng Xu | Chief Technology Officer | – | – |
| Ian Rosenblum | Chief Information Officer | – | – |
| Josh Chen | General Counsel | – | – |
| Kelly Graff | Head of People | – | – |